文献速递肝病胰腺与胆道疾病消化道肿瘤与早癌

基于质谱流式细胞术的外周血分析作为实体瘤早期检测新工具:一项多中心研究

Mass cytometry-based peripheral blood analysis as a novel tool for early detection of solid tumours: a multicentre study.
PubMed 文献 · Gut · 2022-09-16

该多中心研究对来自15个中心的2348名参与者进行质谱流式细胞术(CyTOF)分析,构建基于随机森林算法的诊断模型,计算外周血免疫评分(PBIScore)并联合甲胎蛋白或糖类抗原19-9建立整合评分(iPBIScore)。PBIScore在验证队列中检测肝细胞癌(HCC)和胰腺导管腺癌(PDAC)的敏感度和特异度均约80%;iPBIScore在训练、内部验证和外部验证队列中检测HCC的曲线下面积(AUC)分别为0.99、0.97和0.96,检测PDAC的AUC分别为0.99、0.98和0.97;在早期和肿瘤标志物阴性患者中,基于iPBIScore的模型AUC分别为0.95-0.96和0.81-0.92。

要点

  • PBIScore在验证队列中检测HCC和PDAC的敏感度和特异度均约80%。
  • iPBIScore检测HCC的AUC在训练、内部验证和外部验证队列分别为0.99、0.97和0.96。
  • iPBIScore检测PDAC的AUC在训练、内部验证和外部验证队列分别为0.99、0.98和0.97。

核心结论

  • 外周免疫细胞亚群的改变有助于肿瘤检测,并为HCC和PDAC提供了可用的检测模型。

研究设计与样本

  • 多中心研究,对来自15个中心的2348名参与者进行CyTOF分析,包括1131例肝脏疾病患者、584例胰腺疾病患者和633名健康志愿者。
  • 通过随机森林算法构建诊断模型并在亚组中验证。

主要发现

  • 确定了HCC和PDAC引起的系统性免疫紊乱,并基于构建的模型计算了外周血免疫评分(PBIScore)。
  • PBIScore在验证队列中检测HCC和PDAC的敏感度和特异度均约80%。
  • iPBIScore检测HCC的AUC在训练、内部验证和外部验证队列分别为0.99、0.97和0.96。
  • iPBIScore检测PDAC的AUC在训练、内部验证和外部验证队列分别为0.99、0.98和0.97。
  • 在早期和肿瘤标志物阴性患者中,基于iPBIScore的模型AUC分别为0.95-0.96和0.81-0.92。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Early detection of a tumour remains an unmet medical need, and approaches with high sensitivity and specificity are urgently required. Mass cytometry time-of-flight (CyTOF) is a powerful technique to profile immune cells and could be applied to tumour detection. We attempted to establish diagnostic models for hepatocellular carcinoma (HCC) and pancreatic ductal adenocarcinoma (PDAC). DESIGN: We performed CyTOF analysis for 2348 participants from 15 centres, including 1131 participants with hepatic diseases, 584 participants with pancreatic diseases and 633 healthy volunteers. Diagnostic models were constructed through random forest algorithm and validated in subgroups. RESULTS: We determined the disturbance of systemic immunity caused by HCC and PDAC, and calculated a peripheral blood immune score (PBIScore) based on the constructed model. The PBIScore exhibited good performance in detecting HCC and PDAC, with both sensitivity and specificity being around 80% in the validation cohorts. We further established an integrated PBIScore (iPBIScore) by combining PBIScore and alpha-fetoprotein or carbohydrate antigen 19-9. The iPBIScore for HCC had an area under the curve (AUC) of 0.99, 0.97 and 0.96 in training, internal validation and external validation cohorts, respectively. Similarly, the iPBIScore for PDAC showed an AUC of 0.99, 0.98 and 0.97 in the training, internal validation and external validation cohorts, respectively. In early-stage and tumour-marker-negative patients, our iPBIScore-based models also showed an AUC of 0.95-0.96 and 0.81-0.92, respectively. CONCLUSION: Our study proved that the alterations of peripheral immune cell subsets could assist tumour detection, and provide a ready-to-use detection model for HCC and PDAC.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Zhang Q, Ye M, Lin C, et al. Mass cytometry-based peripheral blood analysis as a novel tool for early detection of solid tumours: a multicentre study. Gut. 2022. PMID: 36113977. doi:10.1136/gutjnl-2022-327496

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。